Profile Image

Dr Gough Au

Conjoint Fellow

School of Biomedical Sciences and Pharmacy (Immunology and Microbiology)

Career Summary

Biography

Dr Gough Au is a conjoint Post Doctoral Research Fellow with the University of Newcastle and works for the Australian oncolytic virotherapy company Viralytics Ltd. Dr Au began his career as a NHMRC Industry Research fellow (2007-2011) carrying out research on the development of naturally occurring viruses with selective anti-cancer properties, for the treatment of melanoma, multiple myeloma and malignant glioma.

Research Expertise
Oncolytic virotherapy, Virology & Cancer Biology

Teaching Expertise
PHAR6124 Virology Lectures HUBS3204 Lab Professional Skills - Commercialisation of Science and Biotechnology Startup Companies.

Administrative Expertise
Animal Care and Ethics Committee member (2011- to present) Faculty of Health - Work Health and Safety Group.

Collaborations
Gough's main research interest is in the development of naturally occurring viruses with selective anti-cancer properties, for the treatment of melanoma, multiple myeloma and malignant glioma. Other interests include Oncolytic virotherapy, Virology and Cancer Biology.


Qualifications

  • PhD, University of Newcastle
  • Bachelor of Biomedical Sciences, University of Newcastle
  • Bachelor of Biomedical Sciences (Hons), University of Newcastle

Keywords

  • Carcinogenesis
  • Clinical sciences
  • Oncology
  • oncolytic virotherapy
  • virology

Fields of Research

CodeDescriptionPercentage
030499Medicinal and Biomolecular Chemistry not elsewhere classified35
111299Oncology and Carcinogenesis not elsewhere classified30
110399Clinical Sciences not elsewhere classified35

Professional Experience

UON Appointment

DatesTitleOrganisation / Department
1/05/2010 - 30/04/2011Research FellowUniversity of Newcastle
School of Biomedical Sciences and Pharmacy
Australia

Academic appointment

DatesTitleOrganisation / Department
1/05/2007 - 1/04/2011FellowUniversity of Newcastle
School of Biomedical Sciences and Pharmacy
Australia
1/05/2007 - NHMRC Industry FellowUniversity of Newcastle
School of Biomedical Sciences and Pharmacy
Australia
1/08/2004 - 1/05/2007Research Director
Research Director/Post Doctoral Scientist
The University of Newcastle Research Associates
School of Biomedical Sciences and Pharmacy
Australia
Edit

Publications

For publications that are currently unpublished or in-press, details are shown in italics.


Journal article (12 outputs)

YearCitationAltmetricsLink
2014McIlroy DJ, Jarnicki AG, Au GG, Lott N, Smith DW, Hansbro PM, Balogh ZJ, 'Mitochondrial DNA neutrophil extracellular traps are formed after trauma and subsequent surgery', Journal of Critical Care, 29 1133.e1-1133.e5 (2014)
DOI10.1016/j.jcrc.2014.07.013
Co-authorsPhilip Hansbro, Douglas Smith, Zsolt Balogh
2014McIlroy DJ, Jarnicki AG, Au GG, Lott N, Smith DW, Hansbro PM, Balogh ZJ, 'Mitochondrial DNA neutrophil extracellular traps are formed after trauma and subsequent surgery', Journal of Critical Care, 29 1133.e1-1133.e5 (2014) [C1]

Introduction: Neutrophil extracellular traps (NETs) have not been demonstrated after trauma and subsequent surgery. Neutrophil extracellular traps are formed from pure mitochondrial DNA (mtDNA) under certain conditions, which is potently proinflammatory. We hypothesized that injury and orthopedic trauma surgery would induce NET production with mtDNA as a structural component. Methods: Neutrophils were isolated 8 trauma patients requiring orthopedic surgery postinjury and up to 5 days postoperatively. Four healthy volunteers provided positive and negative controls. Total hip replacement patients acted as an uninjured surgical control group. Neutrophil extracellular traps were visualized with DNA (Hoechst 33342TM/Sytox Green/MitoSox/MitoTracker) stains using live cell fluorescence microscopy with downstream quantitative polymerase chain reaction analysis of DNA composition. Results: Neutrophil extracellular traps were present after injury in all 8 trauma patients. They persisted for 5 days postoperatively. Delayed surgery resulted in NET resolution, but they reformed postoperatively. Total hip replacement patients developed NETs postoperatively, which resolved by day 5. Quantitative polymerase chain reaction analysis of NET-DNA composition revealed that NETs formed after injury and surgery were made of mtDNA with no detectable nuclear DNA component. Conclusions: Neutrophil extracellular traps formed after major trauma and subsequent surgery contain mtDNA and represent a novel marker of heightened innate immune activation. They could be considered when timing surgery after trauma to prevent systemic NET-induced inflammatory complications.

DOI10.1016/j.jcrc.2014.07.013
CitationsScopus - 3
Co-authorsZsolt Balogh, Douglas Smith, Philip Hansbro
2014McIlroy DJ, Jarnicki AG, Au GG, Lott N, Smith DW, Hansbro PM, Balogh ZJ, 'Mitochondrial DNA neutrophil extracellular traps are formed after trauma and subsequent surgery.', Journal of critical care, 29 1133.e1-1133.e5 (2014) [C1]
DOI10.1016/j.jcrc.2014.07.013
CitationsScopus - 1
Co-authorsDouglas Smith, Philip Hansbro, Zsolt Balogh
2013Kok CC, Au GG, 'Novel marker for recombination in the 3'-untranslated region of members of the species Human enterovirus A', ARCHIVES OF VIROLOGY, 158 765-773 (2013) [C1]
DOI10.1007/s00705-012-1533-2Author URL
CitationsWeb of Science - 1
2011Au GG, Beagley LG, Haley ES, Barry RD, Shafren DR, 'Oncolysis of malignant human melanoma tumors by Coxsackieviruses A13, A15 and A18', Virology Journal, 8 1-6 (2011) [C1]
DOI10.1186/1743-422x-8-22
CitationsScopus - 5Web of Science - 4
2009Haley ES, Au GG, Carlton BR, Barry RD, Shafren DR, 'Regional administration of oncolytic Echovirus 1 as a novel therapy for the peritoneal dissemination of gastric cancer', Journal of Molecular Medicine, 87 385-399 (2009) [C1]
DOI10.1007/s00109-008-0433-0
CitationsScopus - 5Web of Science - 4
2008Howland LJ, Au GG, Barry RD, Shafren DR, 'Potent oncolytic activity of human enteroviruses against human prostate cancer', Prostate, 68 577-587 (2008) [C1]
DOI10.1002/pros.20741
CitationsScopus - 12Web of Science - 11
2007Au GG, Lincz L, Enno A, Shafren DR, 'Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma', British Journal of Haematology, 137 133-141 (2007) [C1]
DOI10.1111/j.1365-2141.2007.06550.x
CitationsScopus - 21Web of Science - 18
Co-authorsLisa Lincz
2004Hansbro NG, Johansson ES, Au GG, Lindberg A, Barry RD, Shafren DR, 'Enterovirus capsid interactions with decay-accelerating factor mediate lytic cell infection', Journal of Virology, 78 1431-1439 (2004) [C1]
DOI10.1128/JVI.78.3.1431-1439.2004
CitationsScopus - 6Web of Science - 5
Co-authorsNicole Hansbro
2004Shafren DR, Au GG, Nguyen T, Barry RD, Hansbro NG, Harvey ES, et al., 'Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, Coxsackievirus A21', Clinical Cancer Research, 10 53-60 (2004) [C1]
DOI10.1158/1078-0432.CCR-0690-3
CitationsScopus - 44Web of Science - 45
Co-authorsErin Harvey, Nicole Hansbro
2003Newcombe NG, Andersson P, Johansson ES, Au GG, Lindberg AM, Barry RD, Shafren DR, 'Cellular receptor interactions of C-cluster human group A coxsackieviruses', JOURNAL OF GENERAL VIROLOGY, 84 3041-3050 (2003)
DOI10.1099/vir.0.19329-0Author URL
CitationsScopus - 28Web of Science - 28
2000Tooney PA, Au GG, Chahl LA, 'Localisation of tachykinin NK1 and NK3 receptors in the human prefrontal and visual cortex', Neuroscience Letters, 283 185-188 (2000) [C1]
CitationsScopus - 34Web of Science - 36
Co-authorsPaul Tooney
Show 9 more journal articles

Conference (11 outputs)

YearCitationAltmetricsLink
2014Shafren D, Quah M, Wong Y, Andtbacka RH, Au G, 'Combination of a novel oncolyticimmunotherapeutic agent, CAVATAK (coxsackievirus A21) and immune-checkpoint blockade significantly reduces tumor growth and improves survival in an immune competent mouse melanoma model', Journal for ImmunoTherapy of Cancer, National Harbour, MD (2014) [E3]
DOI10.1186/2051-1426-2-S3-P125Author URL
2014Simpson GR, Ajaz M, Launchbury FA, Bolton G, Melcher AA, Harrington KJ, et al., 'Major synergy between Coxsackievirus A21 (CAVATAK (TM)) and radiotherapy or chemotherapy in bladder cancer', HUMAN GENE THERAPY, Lincoln Coll & Examinat Sch, Oxford, ENGLAND (2014) [E3]
Author URL
2014Wong YVY, Quah MY, Shafren DR, Au GG, 'Synergistic Activity of Coxsackievirus A21 (CVA21) and Docetaxel in Non-Small Cell Lung Cancer (NSCLC)', HUMAN GENE THERAPY, Lincoln Coll & Examinat Sch, Oxford, ENGLAND (2014) [E3]
Author URL
2011Yee YWV, Chan SHE, Shafren DR, Au GG, 'Oncolytic activity of coxsackievirus A21 in human lung cancer: A novel targeted anti-cancer strategy', Journal of Thoracic Oncology, Amsterdam, The Netherlands (2011) [E3]
2011Shafren DR, Farrelly M, Croft AJ, Davies B, Stewart J, Ingham R, et al., 'CAVATAK (Coxsackievirus A21) displays potent oncolytic activity in BRAFV600E mutant melanoma cells resistant to selective BRAF kinase inhibitors', Pigment Cell & Melanoma Research, Tampa, FL (2011) [E3]
DOI10.1111/j.1755-148X.2011.00909.x
2011Shafren DR, Au GG, Davies B, Chan E, Stewart J, 'Pre-clinical oncolytic activity of coxsackievirus a21 in pancreatic cancer', Annals of Oncology, Barcelona, Spain (2011) [E3]
2007Skelding KA, Johansson ES, Au GG, Barry RD, Shafren DR, 'CAVATAK TM has anti-cancer properties against human metastatic breast cancer', Fourth International Conference on Oncolytic Viruses as Cancer Therapeutics, Carefree, Arizona (2007) [E3]
Co-authorsKathryn Skelding
2006Au GG, Johansson ES, Berry L, Skelding KA, Haley ES, Barry RD, Shafren DR, 'Coxsackievirus A21 as an oncolytic virotherapy agent for human cancers', Northern Lights EUROPIC 2006, Inari, Finland (2006) [E3]
Co-authorsKathryn Skelding
2005Shafren DR, Au GG, Berry LJ, Haley ES, Skelding KA, Barry RD, 'The human enterovirus, Coxsackievirus A21, exhibits oncolytic activity across a spectrum of cancer types', Proceedings of the 96th American Association for Cancer Research Annual Meeting, Anaheim, California (2005) [E3]
Co-authorsKathryn Skelding
2005Berry LJ, Haley ES, Skelding KA, Au GG, Barry RD, Shafren DR, 'Oncolytic activity of enteroviruses across a spectrum of human cancer types', Third Annual Australian Virology Group Meeting, Phillip Island, VIC (2005) [E3]
Co-authorsKathryn Skelding
2000Tooney PA, Au GG, Chahl LA, 'Tachykinin NK1 and NK3 receptors in the prefrontal cortex of the human brain', Proceedings of the Australian Physiological and Pharmacological Society Symposium Tachykinins: The Challenge Continues, Newcastle, Australia (2000) [E1]
CitationsScopus - 27Web of Science - 26
Co-authorsPaul Tooney
Show 8 more conferences
Edit

Grants and Funding

Summary

Number of grants9
Total funding$595,774

Click on a grant title below to expand the full details for that specific grant.


20113 grants / $96,500

Maitland Cancer Appeal Committee Donation - Lung Cancer Mouse Model$50,000

Funding body: Maitland Cancer Appeal Committee

Funding bodyMaitland Cancer Appeal Committee
Project TeamProfessor Phil Hansbro, Laureate Professor Paul Foster, Doctor Gough Au
SchemeResearch Project
RoleInvestigator
Funding Start2011
Funding Finish2011
GNoG1100246
Type Of FundingDonation - Aust Non Government
Category3AFD
UONY

SCIREQ FlexiVentFX system + FlexiVentFX extension$45,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding bodyNHMRC (National Health & Medical Research Council)
Project TeamProfessor Phil Hansbro, Laureate Professor Paul Foster, Professor Joerg Mattes, Doctor Simon Keely, Doctor Jay Horvat, Doctor Nicole Hansbro, Doctor Ming Yang, Doctor Catherine Ptaschinski, Doctor Kelly Asquith, Doctor Gough Au, Conjoint Professor Peter Wark, Laureate Professor John Aitken, Conjoint Professor Keith Jones, Professor Roger Smith, Professor Judith Black, Professor Rakesh Kumar, Professor Paul Hertzog
SchemeEquipment Grant
RoleInvestigator
Funding Start2011
Funding Finish2011
GNoG1100037
Type Of FundingOther Public Sector - Commonwealth
Category2OPC
UONY

World Cancer Congress 2011, World Expo Center, Dalian, China, 22 - 25 May 2011$1,500

Funding body: University of Newcastle - Faculty of Health and Medicine

Funding bodyUniversity of Newcastle - Faculty of Health and Medicine
Project TeamDoctor Gough Au
SchemeTravel Grant
RoleLead
Funding Start2011
Funding Finish2011
GNoG1100576
Type Of FundingInternal
CategoryINTE
UONY

20101 grants / $85,188

Control of malignant glioma by naturally occurring oncolytic enteroviruses.$85,188

Funding body: Cancer Australia

Funding bodyCancer Australia
Project TeamDoctor Gough Au
SchemePriority-driven Collaborative Cancer Research Scheme
RoleLead
Funding Start2010
Funding Finish2010
GNoG0190325
Type Of FundingAust Competitive - Commonwealth
Category1CS
UONY

20092 grants / $31,700

The use of Coxsackievirus A21 as a therapy for multiple myeloma and malignant glioma$30,000

Funding body: Ramaciotti Foundations

Funding bodyRamaciotti Foundations
Project TeamDoctor Gough Au
SchemeEstablishment Grant
RoleLead
Funding Start2009
Funding Finish2009
GNoG0189325
Type Of FundingGrant - Aust Non Government
Category3AFG
UONY

5th International Meeting on Replicating Oncolytic Virus Therapeutics, Banff Canada, 18-21 March 2009$1,700

Funding body: University of Newcastle - Faculty of Health and Medicine

Funding bodyUniversity of Newcastle - Faculty of Health and Medicine
Project TeamDoctor Gough Au
SchemeTravel Grant
RoleLead
Funding Start2009
Funding Finish2009
GNoG0189949
Type Of FundingInternal
CategoryINTE
UONY

20081 grants / $5,379

New Staff Grant$5,379

Funding body: University of Newcastle

Funding bodyUniversity of Newcastle
Project TeamDoctor Gough Au
SchemeNew Staff Grant
RoleLead
Funding Start2008
Funding Finish2008
GNoG0188610
Type Of FundingInternal
CategoryINTE
UONY

20072 grants / $377,007

Coxsackievirus A21 virotherapy of multiple myeloma and malignant glioma$369,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding bodyNHMRC (National Health & Medical Research Council)
Project TeamDoctor Gough Au
SchemeIndustry Research Fellowships
RoleLead
Funding Start2007
Funding Finish2007
GNoG0186779
Type Of FundingAust Competitive - Commonwealth
Category1CS
UONY

The use of Coxsackie B group viruses as potential treatments for human gastric and colorectal cancers$8,007

Funding body: University of Newcastle

Funding bodyUniversity of Newcastle
Project TeamDoctor Gough Au
SchemeEarly Career Researcher Grant
RoleLead
Funding Start2007
Funding Finish2007
GNoG0188074
Type Of FundingInternal
CategoryINTE
UONY
Edit

Research Supervision

Current Supervision

CommencedResearch Title / Program / Supervisor Type
2014Investigation of Oncolytic CVA21 as a Potential Treatment for Pancreatic Cancer
Microbiology, Faculty of Health and Medicine
Principal Supervisor
2012Investigating the Mechanisms of Tobacco Cigarette Smoke-Induced Lung Cancer
Microbiology, Faculty of Health and Medicine
Co-Supervisor
2011Investigation of Oncolytic Coxsackievirus A21 as a Potential Treatment for Lung Cancer
Microbiology, Faculty of Health and Medicine
Principal Supervisor
2011Combination of Oncolytic Coxsackievirus A21 with Conventional Chemotherapy for the Treatment of Melanoma
Microbiology, Faculty of Health and Medicine
Principal Supervisor

Past Supervision

YearResearch Title / Program / Supervisor Type
2014Low Pathogenic Human Enteroviruses as Novel Anti-Cancer Agents Against Malignant Glioma
Microbiology, Faculty of Health and Medicine
Principal Supervisor
Edit

Dr Gough Au

Position

Conjoint Fellow
Viralytics
School of Biomedical Sciences and Pharmacy
Faculty of Health and Medicine

Focus area

Immunology and Microbiology

Contact Details

Emailgough.au@newcastle.edu.au
Phone(02) 404 20253
Fax(02) 404 20027

Office

Room2420
BuildingHMRI building
LocationLevel 2, HMRI Building East Wing

,
Edit